EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Monoamine oxidase-A (MAO-A) low-expression variants and increased risk of Plasmodium vivax malaria relapses

Maria Carolina Silva De Barros Puça, Danielle Fonseca Rodrigues, Yanka Evellyn Alves Rodrigues Salazar, Jaime Louzada, Cor Jesus Fernandes Fontes, André Daher, Dhélio Batista Pereira, José Luiz Fernandes Vieira, Luzia Helena Carvalho, Cristiana Ferreira Alves de Brito, José Pedro Gil, Tais Nobrega de Sousa iD

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Maria Carolina Silva De Barros Puça und 11 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Biology and Malaria Immunology Research Group, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ), Belo Horizonte, Minas Gerais, Brazil. Hauptthemen laut MEDLINE: Antimalarials, Cytochrome P-450 CYP2D6, Malaria, Vivax, Monoamine Oxidase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Swedish Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Primaquine is essential for the radical cure of Plasmodium vivax malaria and must be metabolized into its bioactive metabolites. Accordingly, polymorphisms in primaquine-metabolizing enzymes can impact the treatment efficacy. This pioneering study explores the influence of monoamine oxidase-A (MAO-A) on primaquine metabolism and its impact on malaria relapses.

Methods

Samples from 205 patients with P. vivax malaria were retrospectively analysed by genotyping polymorphisms in MAO-A and cytochrome P450 2D6 (CYP2D6) genes. We measured the primaquine and carboxyprimaquine blood levels in 100 subjects for whom blood samples were available on the third day of treatment. We also examined the relationship between the enzyme variants and P. vivax malaria relapses in a group of subjects with well-documented relapses.

Results

The median carboxyprimaquine level was significantly reduced in individuals carrying low-expression MAO-A alleles plus impaired CYP2D6. In addition, this group experienced significantly more P. vivax relapses. The low-expression MAO-A status was not associated with malaria relapses when CYP2D6 had normal activity. This suggests that the putative carboxyprimaquine contribution is irrelevant when the CYP2D6 pathway is fully active.

Conclusions

We found evidence that the low-expression MAO-A variants can potentiate the negative impact of impaired CYP2D6 activity, resulting in lower levels of carboxyprimaquine metabolite and multiple relapses. The findings support the hypothesis that carboxyprimaquine may be further metabolized through CYP-mediated pathways generating bioactive metabolites that act against the parasite.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsCytochrome P-450 CYP2D6Malaria, VivaxMonoamine OxidasePrimaquineAdultFemaleHumansMaleMiddle AgedGenotypePlasmodium vivaxPolymorphism, GeneticRecurrenceRetrospective Studies

Substanzen

AntimalarialsCytochrome P-450 CYP2D6Monoamine OxidasePrimaquinemonoamine oxidase A, human

Autor:innen und Institutionen

  • Molecular Biology and Malaria Immunology Research Group, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ), Belo Horizonte, Minas Gerais, Brazil.
  • Universidade Federal de Roraima, Boa Vista, Roraima, Brazil.
  • Universidade Federal do Mato Grosso, Faculdade de Medicina, Departamento de Medicina Interna, Cuiabá, Mato Grosso, Brazil.
  • Vice Presidency of Research and Biological Collections, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Centro de Pesquisa em Medicina Tropical de Rondônia, CEPEM, Porto Velho, Rondônia, Brazil.
  • Universidade Federal do Pará, Faculdade de Farmácia, Laboratório de Toxicologia, Belém, Pará, Brazil.

ORCID-Profile: Tais Nobrega de Sousa

Förderung

  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Swedish Research Council
  • Programa PrInt-Fiocruz-CAPES

Zitieren

APA

Puça, M. C. S. B., Rodrigues, D. F., Salazar, Y. E. A. R., Louzada, J., Fontes, C. J. F., Daher, A., Pereira, D. B., Fernandes Vieira, J. L., Carvalho, L. H., Alves de Brito, C. F., Gil, J. P., & Nobrega de Sousa, T. (2024). Monoamine oxidase-A (MAO-A) low-expression variants and increased risk of Plasmodium vivax malaria relapses. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae196

Vancouver

Puça MCSB, Rodrigues DF, Salazar YEAR, Louzada J, Fontes CJF, Daher A, et al. Monoamine oxidase-A (MAO-A) low-expression variants and increased risk of Plasmodium vivax malaria relapses. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae196

BibTeX
@article{Pua2024,
  author = {Puça, Maria Carolina Silva De Barros and Rodrigues, Danielle Fonseca and Salazar, Yanka Evellyn Alves Rodrigues and Louzada, Jaime and Fontes, Cor Jesus Fernandes and Daher, André and Pereira, Dhélio Batista and Fernandes Vieira, José Luiz and Carvalho, Luzia Helena and Alves de Brito, Cristiana Ferreira and Gil, José Pedro and Nobrega de Sousa, Tais},
  title = {Monoamine oxidase-A (MAO-A) low-expression variants and increased risk of Plasmodium vivax malaria relapses},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae196}
}
Kostenlos starten →